Abstract
The number and diversity of animal models used to study the effectiveness of antiarrhythmic agents attests to the inadequacy of any one model to closely simulate the most frequent and important cause of sudden death in man.(1) Obviously each model is able to imitate certain aspects of the arrhythmias seen in the presence of ischemic heart disease, but significant problems have been identified in relating the arrhythmias induced in these models to those resulting from acute or chronic ischemia in man. In general, these models do not take into account such factors as prior coronary and cardiac disease, neurohumoral influences, collateral circulation, or the anatomical locations of the diseased vessels and infarcted zones, each of which may influence the susceptibility for ventricular arrhythmias to culminate in ventricular fibrillation. While the Harris(2–4) 1 stage and 2 stage coronary artery ligation models introduced more than 30 years ago remain most popular for the study of ventricular arrhythmias associated with myocardial ischemia and infarction, they have not been completely satisfactory as models for anti-arrhythmic drug testing.
Keywords
- Ventricular Arrhythmia
- Ventricular Fibrillation
- Antiarrhythmic Drug
- Coronary Occlusion
- Antiarrhythmic Agent
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fozzard HA: Validity of myocardial infarction models. Circulation Supplement III 51,52:III-131-137, 1975
Harris AS, Rojas AG: The initiation of ventricular fibrillation due to coronary occlusion. Exp Med Surg 1:105, 1943
Harris AS: Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation 1:1318, 1950
Harris AS, Estandia A, Ford TJ Jr, Smith HT, Olsen RW, Tillotson RR: Effect of intravenous procainamide (Pronestyl) upon ectopic ventricular tachycardia accompanying acute myocardial infarction. Circulation 5:551–558, 1952
Mokier CM, Van Arman CG: Pharmacology of a new anti-arrhythmic agent, -Diisopropyl-amino- -phenyl- (2 pyridyl)-butyramede (SC-7031). J Pharm and Experimental Therap 131:114–124, 1962
Lucchesi BR, Whitsitt LS: Antiarrhythmic effects of beta adrenergic blocking agents. Ann NY Acad Sci 139:940–951, 1967
Allen JD, Shanks RG, Zaidi SA: Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharm 42:1–12, 1971
Danilo P Jr, Langan WB, Rosen MR, Hoffman BF: Effects of the phenothiazine analog, EN-313, on ventricular arrhythmias in the dog. Europ J of Pharm 45:127–139, 1977
Friedman PL, Stewart JR, Fenoglio JJ Jr, Wit AL: Survival of subendocardial Purkinje fibers after extensive myocardial infarction in dogs: In vitro and in vivo correlations. Circ Res 33:597–611, 1973
Friedman PL, Stewart JR, Wit AL: Spontaneous and induced cardiac arrhythmias in subendocardial Purkinje fibers surviving extensive myocardial infarction in dogs. Circ Res 33:612–626, 1973
Horowitz LN, Spear JF, Moore EN: Subendocardial origin of ventricular arrhythmias in 24 hour old experimental myocardial infarction. Circulation 53:56–63, 1976
Elharrar V, Gaum WE, Zipes DP: Effect of drugs on conduction delay and the incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol 39:544–549, 1977
Battle WE, Naimi S, Avitall B, Brilla AH, Banas JS Jr, Bate JM, Levine HG: Distinctive time course of ventricular vulnerability to fibrillation during and after release of coronary ligation. Am J Cardiol 34:42–47, 1974
Williams DO, Scherlag BJ, Hope RR, El Sherif N, Lazzara R: The pathophysiology of malignant ventricular arrhythmias during acute myocardial ischemia. Circulation 50:1163–1172, 1974
Kaplinsky E, Ogawa S, Balke CW, Dreifus LS: Two periods of early ventricular arrhythmias in the canine acute myocardial infarction model. Circulation 60:397–403, 1979
Corbalan R, Verrier RL, Lown B: Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release. Am Heart J 92:223–229, 1976
Balke CW, Kaplinsky E, Michelson EL, Dreifus LS: Limitations of sequential coronary reperfusion as a model for antiarrhythmic drug evaluation. Circulation Suppl II:II-87, 1979
Laadt JR, Allen JB: The effect of quinidine on ventricular fibrillation induced by coronary ligation. Am Heart J 39:279–282, 1950
Stephenson SE, Cole RK, Parrish TF, et al: Ventricular fibrillation during and after coronary occlusion: Incidence and protection afforded by various drugs. Am J Cardiol Jan:77–87, 1960
Weisse AB, Moschos CB, Passannante AJ, Khan MI, Regan TJ: Relative effectiveness of three antiarrhythmic agents in the treatment of ventricular arrhythmias in experimental acute myocardial ischemia. Am Heart J 81:503–510, 1971
Gamble OW, Cohn K: Effect of propranolol, procainamide and lidocaine on ventricular automaticity and reentry in experimental myocardial infarction. Circulation 46:498–506, 1972
Khan MI, Hamilton JT, Manning GW: Early arrhythmias following experimental coronary occlusion in conscious dogs and their modification of beta adrenoceptor blocking drugs. Am Heart J 86:347–358, 1973
Myers RW, Pearlman AS, Hymen RM, et al: Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia. Circulation 49:943–947, 1974
Borer JS, Kent KM, Goldstein RE, Epstein SE: Nitroglycerine induced reduction in the incidence of spontaneous ventricular fibrillation during coronary occlusion in dogs. Am J Cardiol 33:517, 1974
Kniffen FJ, Lomas TE, Counsell RE, Lucchesi BR: The antiarrhythmic and antifibrillatory actions of bretylium and its 0-iodobenzyl trimethylammonium analog, UM-360. J Pharm and Exper Therap 92:120–128, 1975
Rosenbaum MB, Chiale PA, Halpern MS, Nau G, et al: Antiarrhythmic efficacy of amiodarone. Am J Cardiol 38:934–944, 1976
Verdouw PD, Remme WJ, Hugenholtz PG: Cardiovascular and antiarrhythmic effects of aprindine (AC 1802) during partial occlusion of a coronary artery in the pig. Cardiovasc Res 11:317–323, 1977
Naito M, Michelson EL, Kmetzo JJ, Kaplinsky E, Dreifus LS: Failure of antiarrhythmic drugs to prevent experimental reperfusion ventricular fibrillation. Circulation 63:Jan, 1981 (In Press)
Williams DO, Scherlag BJ, Hope RR, El Sherif, N, Lazzara R: The pathophysiology of malignant ventricular arrhythmias during acute myocardial ischemia. Circulation 50:1163–1172, 1964
Balke CW, Kaplinsky E, Michelson EL, Naito M, Dreifus LS: Reperfusion ventricular arrhythmias: Correlation with antecedent coronary artery ligation arrhythmias and duration of acute ligation. Am Heart J (submitted)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Martinus Nijhojf Publishers bv, The Hague.
About this chapter
Cite this chapter
Dreifus, L.S., Naito, M., Michelson, E.L. (1981). What Animal Models Should Be Used to Define Antiarrhythmic Efficacy? Acute Dog Models. In: Morganroth, J., Moore, E.N., Dreifus, L.S., Michelson, E.L. (eds) The Evaluation of New Antiarrhythmic Drugs. Developments in Cardiovascular Medicine, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8270-3_3
Download citation
DOI: https://doi.org/10.1007/978-94-009-8270-3_3
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-8272-7
Online ISBN: 978-94-009-8270-3
eBook Packages: Springer Book Archive